Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Harbin
Clinical trial register · China

Clinical Trials in Harbin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Harbin Medical University24 AstraZeneca23 Eli Lilly and Company21 BeOne Medicines15 Hoffmann-La Roche15
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Harbin

548 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Beijing, Chongqing, Guangzhou, Guiyang, Harbin, Wuhan, Changsha, Nanjing
2027-11-23
Not yet open
Eli Lilly and Company
Phase 3
192
Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Luoyang Shi, Nanchang
2026-12
Not yet open
Eli Lilly and Company
Phase 3
3,000
Beijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Liaoyou, Luoyang Shi
2026-12
Not yet open
Shanghai Henlius Biotech
Phase 2/3
1,438
Hefei, Beijing, Chongqing, Nanning, Zunyi, Shijiazhuang, Harbin, Anyang
2026-11-30
Not yet open
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
270
Fuzhou, Harbin, Changsha, Nanchang, Changchun, Shanghai, Taizhou
2026-11-01
Not yet open
Hansoh BioMedical R&D Company
Phase 3
460
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shaoguan, Nanning, Harbin
2026-11-01
Not yet open
Eddingpharm (Zhuhai) Co., Ltd.
Phase 2
144
Harbin, Zhejiang
2026-11
Recruiting
GST101 in Participants With RAS-Mutant Advanced Solid Tumors
NCT07868172RAS-mutant Advanced Solid Tumors
Genuine Seed Therapeutics (Zhuhai) Co., Ltd.
Phase 1/2
172
Harbin, Wuhan, Jinan, Shanghai, Chengdu, Hangzhou
2026-10-30
Not yet open
Bisirna Therapeutics (Suzhou) Co., Ltd.
Phase 3
70
Beijing, Jilin City, Quanzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2026-10-29
Not yet open
Clinical Trial of SEEG for Drug-resistant Epilepsy
NCT07923058Drug-Resistant Epilepsy
Beijing Pins Medical Co., Ltd
Not applicable
99
Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Wuhan, Changsha, Jinan
2026-10-23
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
184
Beijing, Fuzhou, Lanzhou, Guangzhou, Guiyang, Baoding, Harbin, Zhengzhou
2026-10-22
Not yet open
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
64
Beijing, Lanzhou, Foshan, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2026-10-20
Recruiting
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsDS-1103a·DS-3939a·Pemetrexed·Carboplatin
Daiichi Sankyo
Phase 1/2
400
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Hexi District, Tianjin, Jiamusi
2026-10-13
Not yet open
Beijing QL Biopharmaceutical Co.,Ltd
Phase 2
210
Beijing, Huizhou, Handan, Langfang, Harbin, Nanyang, Yichang, Changde
2026-10-12
Not yet open
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
560
Harbin, Shanghai
2026-10-08
Recruiting
Boehringer Ingelheim
Phase 1/2
55
Chengdu, Harbin, Shanghai
2026-10-01
Not yet open
Shanghai Mental Health Center
Observational
500
Chaohu, Hefei, Beijing, Fuzhou, Foshan, Shantou, Zhongshan, Harbin
2026-10-01
Not yet open
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2
288
Harbin
2026-09-30
Recruiting
Akeso
Phase 1
243
Harbin, Shanghai, Chengdu
2026-09-30
Recruiting
Pfizer
Phase 3
300
Hefei, Beijing, Chongqing, Huizhou, Hengshui, Shijiazhuang, Harbin, Luoyang
2026-09-24
Not yet open
Renal Oxygenation-Guided AKI Reduction Trial
NCT07816640Acute Kidney Injury, Hepatectomy
Chinese PLA General Hospital
Not applicable
1,200
Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2026-09-20
Not yet open
First Affiliated Hospital of Harbin Medical University
Not applicable
450
Harbin
2026-09-18
Recruiting
Vividion Therapeutics, Inc.
Phase 2
140
Bengbu, Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Jinan, Shanghai
2026-09-11
Not yet open
Zhao Minghui
Phase 3
70
Fuzhou, Guangzhou, Harbin, Nanjing, Xuzhou, Nanchang, Shenyang, Yantai
2026-09-10
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
71
Beijing, Chongqing, Lanzhou, Foshan, Guangzhou, Nanning, Zunyi, Harbin
2026-09-03
Not yet open
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
NCT07466251Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque
DrugRecaticimab
Peking Union Medical College Hospital
Phase 4
1,212
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2026-09-01
Recruiting
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
222
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Xi'an, Jinan
2026-09
Not yet open
Dizal Pharmaceuticals
Phase 2/3
880
Chongqing, Harbin, Changsha, Jinan, Shanghai
2026-09
Recruiting
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
NCT07776522Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
DrugAflibercept
West China Hospital
Phase 2
50
Beijing, Jilin City, Chongqing, Shantou, Zhejiang, Harbin, Zhengzhou, Wuhan
2026-08-31
Not yet open
A Phase 2 Study of ABSK043 Combined With Osimertinib
NCT07710612Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
DrugsABSK043·Osimertinib
Abbisko Therapeutics Co, Ltd
Phase 2
72
Guangzhou, Harbin, Wuhan, Shenyang, Shanghai, Taiyuan, Hangzhou
2026-08-31
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
145
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Shanghai
2026-08-25
Not yet open
Beijing University of Chinese Medicine
Not applicable
400
Guangzhou, Guiyang, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Chengdu
2026-08-01
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Daqing, Harbin, Wuhan
2026-07-31
Not yet open
Shanghai Zhongshan Hospital
Observational
400
Guangzhou, Nanning, Harbin, Qingdao, Shanghai, Kunming
2026-07-31
Not yet open
Harbin Medical University
Phase 2
120
Harbin
2026-07-30
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
10
Harbin
2026-07-30
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
80
Beijing, Hangzhou, Changsha, Harbin, Nanjing, Shanghai, Taiyuan, Wuhan
2026-07-16
Recruiting
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
NCT07567625Acute Myocardial Infarction (AMI), ST-Segment Elevation Myocardial Infarction(STEMI), Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)
Harbin Medical University
Not applicable
2,000
Harbin, Beijing, Cangzhou, Chengde, Chengdu, Dalian, Daqing, Hunan
2026-07-13
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1/2
294
Guangzhou, Harbin, Zhengzhou, Chengdu
2026-07-10
By invitation
Novo Nordisk A/S
Observational
216
Beijing, Chongqing, Lanzhou, Jiangmen, Langfang, Harbin, Shiyan, Huai'an
2026-07-02
Recruiting
Genmab
Phase 3
82
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan
2026-06-26
Recruiting
Vantive Health LLC
Observational
750
Beijing, Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha
2026-06-17
Not yet open
Shanghai Best-Link Bioscience, LLC
Phase 1
33
Harbin, Zhengzhou, Wuhan, Changzhou, Shenyang, Taizhou, Shanghai
2026-06-16
Not yet open
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
NCT07699770Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
DrugCrisugabalin
Tang-Du Hospital
Phase 4
110
Beijing, Chongqing, Harbin, Hohhot, Changchun, Shenyang, Xi'an, Ürümqi
2026-06-15
Active, closed
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
NCT07791602Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
DrugCamrelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
180
Beijing, Harbin, Shenyang, Taiyuan, Tianjin
2026-06-12
Recruiting
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
60
Fuzhou, Guangzhou, Liuzhou, Yulin, Baoding, Chengde, Tangshan, Harbin
2026-06-11
Recruiting
Harbin Medical University
Not applicable
150
Fuzhou, Nanning, Shijiazhuang, Harbin, Qiqihar, Wuhan, Baotou, Hohhot
2026-06-10
Active, closed
Harbin Medical University
Phase 2
96
Harbin
2026-06-10
Not yet open
Akeso
Phase 1/2
286
Beijing, Harbin, Chengdu
2026-06-06
Recruiting
A Phase I Study of JSKN021 in Advanced Solid Tumors
NCT07617727Advanced Malignant Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1
199
Fuzhou, Nanning, Harbin, Wuhan, Nanjing, Xuzhou, Jining, Shanghai
2026-06-02
Not yet open
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
NCT07623642Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
DrugGV20-0251
GV20 Therapeutics
Phase 2
227
Beijing, Harbin
2026-06-02
Active, closed
Harbin Medical University
Phase 2
58
Harbin
2026-06-01
Recruiting
Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma
NCT07652489Adenoid Cystic Carcinoma, Sinonasal Carcinoma
Eye & ENT Hospital of Fudan University
Observational
70
Harbin, Changsha, Shenyang, Shanghai, Xi’an, Wenzhou
2026-06-01
Recruiting
Shanghai Zhongshan Hospital
Observational
333
Beijing, Guangzhou, Shenzhen, Naning, Harbin, Zhengzhou, Wuhan, Nanjing
2026-06
Recruiting
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
NCT07528027Hypertension With Overweight or Obesity
DrugHRS-7535
Shandong Suncadia Medicine Co., Ltd.
Phase 3
648
Beijing, Harbin
2026-05-29
Active, closed
Harbin Medical University
Phase 2
43
Harbin
2026-05-29
Active, closed
Harbin Medical University
Phase 2
44
Harbin
2026-05-27
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
178
Beijing, Harbin, Tianjin
2026-05-27
Recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2
36
Harbin
2026-05-25
Recruiting
AbbVie
Phase 3
990
Beijing, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Wuxi, Changchun
2026-05-22
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
160
Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin, Luoyang
2026-05-20
Recruiting
Huahui Health
Phase 1/2
30
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou
2026-05-19
Recruiting
FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis
NCT07511309Atherosclerotic Renal Artery Stenosis, Fractional Flow Reserve, Optimal Medical Therapy, Stent Implantation
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
300
Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Changchun, Jinan
2026-05-15
Active, closed
Harbin Medical University
Observational
1,000
Harbin
2026-05-13
Recruiting
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
NCT07444372Obstructive Sleep Apnea, Sleep Disorder (Disorder), Atrial Fibrillation (AF), Sleep Disordered Breathing (SDB)
Beijing Anzhen Hospital
Not applicable
658
Beijing, Fuzhou, Zhangzhou, Nanning, Langfang, Shijiazhuang, Xingtai, Harbin
2026-05-12
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Guangzhou, Shijiazhuang, Harbin, Changsha, Baotou, Changzhou, Nanjing, Suzhou
2026-05-11
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Beijing, Lanzhou, Foshan, Guangzhou, Harbin, Changsha, Baotou, Nanjing
2026-05-11
Recruiting
SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)
NCT07316270AF - Atrial Fibrillation, Intracranial Hemorrhage, Spontaneous
Beijing Anzhen Hospital
Not applicable
646
Hefei, Beijing, Xiamen, Harbin, Changchun, Xi'an
2026-05-06
Recruiting
Gan Lijun
Not applicable
2,170
Beijing, Haikou, Harbin, Nanchang, Heze, Jinan, Jining, Liaocheng
2026-05-04
Not yet open
Covered vs Bare Metal Stents for Atherosclerotic Renal Artery Stenosis
NCT07566065Atherosclerotic Renal Artery Stenosis, Hypertension, Renal Artery Stenosis
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
150
Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Jinan, Qingdao
2026-04-30
Recruiting
Multitude Therapeutics Inc.
Phase 2
180
Fuzhou, Nanning, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Shengyang
2026-04-29
Recruiting
Bayer
Phase 2
250
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2026-04-27
By invitation
Harbin Medical University
Not applicable
14,980
Daqing, Harbin, Hegang, Jiamusi, Mudanjiang, Qiqihar, Shuangyashan, Suihua
2026-04-27
Not yet open
Shanghai Henlius Biotech
Phase 2
180
Harbin
2026-04-25
Recruiting
SKB103 for Injection in Advanced Solid Tumors
NCT07459998Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
277
Harbin, Shanghai
2026-04-23
Recruiting
Beijing Shijitan Hospital, Capital Medical University
Observational
129
Beijing, Harbin, Dalian, Weifang
2026-04-20
Not yet open
Second Xiangya Hospital of Central South University
Not applicable
472
Quanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changde, Changsha, Loudi
2026-04-18
Recruiting
Xuanwu Hospital, Beijing
Not applicable
264
Beijing, Fuzhou, Shijiazhuang, Harbin, Nanyang, Zhengzhou, Baotou, Xi'an
2026-04-15
Recruiting
Boehringer Ingelheim
Phase 3
670
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-04-13
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Beijing, Harbin, Zhengzhou
2026-04-02
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Beijing, Chongqing, Guangdong, Harbin, Zhengzhou, Wuhan, Changsha, Changchun
2026-04-02
Recruiting
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
Recruiting
Fujian Medical University
Not applicable
1,312
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Dalian
2026-03-29
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Binzhou, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Harbin, Hefei
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Beijing, Guangzhou, Tianjin, Harbin, Changsha Shi, Nanjing, Shanghai Shi
2026-03-26
Recruiting
DXP-106 in Solid Tumor Patients.
NCT07532018Solid Tumor, Cancer
Singlomics Biopharmaceuticals Zhuhai Co., Ltd.
Phase 1
54
Harbin, Shanghai, Taiyuan, Hangzhou
2026-03-23
Recruiting
Tamsulosin for Early Catheter Removal After Rectal Cancer Surgery
NCT07346586Urinary Catheters, Rectal Cancer, Urinary Retention
The First Hospital of Jilin University
Not applicable
1,545
Harbin, Changchun
2026-03-18
Recruiting
Bristol-Myers Squibb
Phase 1/2
198
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Nanyang
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Weihui, Zhengzhou, Wuhan
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Beijing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Shantou, Nanning, Harbin
2026-03-12
Active, closed
Harbin Medical University
Phase 2
30
Harbin
2026-03-04
Not yet open
Dermavon Holdings Limited
Phase 2/3
540
Bengbu, Wuhu, Guangzhou, Chengde, Handan, Shijiazhuang, Harbin, Nanyang
2026-03-03
Recruiting
Janssen Research & Development, LLC
Phase 1/2
60
Guangzhou, Harbin, Shanghai
2026-03-03
Recruiting
West China Hospital
Observational
2,000
Hefei, Chongqing, Guangzhou, Harbin, Wuhan, Nanjing, Tianjin
2026-03-01
Active, closed
Ribotek Biopharmaceuticals (Shandong) Co., Ltd
Phase 2
40
Daqing, Harbin, Luoyang, Jingzhou, Nanyang, Yuncheng, Beijing
2026-02-28
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
465
Beijing, Chongqing, Guangzhou, Guanzhou, Zhongshan, Nanning, Cangzhou, Harbin
2026-02-26
Recruiting
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
AstraZeneca
Phase 3
2,130
Beijing, Changde, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-02-03
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
111
Harbin, Hefei, Shanghai, Xi'an, Zhengzhou
2026-02-01
Not yet open
The Third Affiliated Hospital of Harbin Medical University
Phase 2
47
Harbin
2026-02-01
Not yet open
Yanqiao Zhang
Phase 2
30
Harbin
2026-02
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
170
Beijing, Fuzhou, Guangzhou, Jiangmen, Harbin, Nanchang, Shanghai, Chengdu
2026-01-29
Active, closed
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
NCT07462923Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
DrugRis-Rez
Hansoh BioMedical R&D Company
Phase 1
40
Beijing, Fuzhou, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha
2026-01-29
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
220
Guangzhou, Harbin, Zhengzhou, Nanjing, Changchun, Shenyang
2026-01-27
Active, closed
Time-Restricted Eating for Weight-Loss Maintenance
NCT07163455Overweight or Obese Adults
Harbin Medical University
Not applicable
500
Beijing, Chongqing, Shenzhen, Harbin, Xi'an, Qingdao, Weifang, Chengdu
2026-01-26
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
190
Bengbu, Chaoyang, Fuzhou, Guandong, Harbin, Wuhan, Changsha, Nanchang
2026-01-26
Recruiting
BeOne Medicines
Phase 3
500
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Harbin, Zhengzhou
2026-01-22
Recruiting
First in Human Study of SIM0610 in Solid Tumors
NCT07348211Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
260
Chongqing, Harbin, Shenyang, Jinan, Shanghai
2026-01-19
Recruiting
Boehringer Ingelheim
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan
2026-01-16
Recruiting
Innostellar Biotherapeutics Co.,Ltd
Phase 3
388
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Zhongshan, Xingtai, Harbin
2026-01-14
Recruiting
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2
210
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Xuzhou, Shenyang
2026-01-08
Not yet open
Critical Illness After Hematopoietic Cell Transplantation
NCT07328724Critical Illness, Ventilated Patients, Hematopoetic Stem Cell Transplantation, Transplant Complication
Peking University People's Hospital
Observational
4,000
Beijing, Chongqing, Hangzhou, Harbin, Tianjin, Wuhan
2026-01-01
Not yet open
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4
174
Beijing, Foshan, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jilin City
2026-01-01
Recruiting
Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation
NCT07349498Hematopoietic Stem Cell Transplantation, Transplant Complication, Cardiovascular Events
Peking University People's Hospital
Observational
10,000
Beijing, Chongqing, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Xi'an
2026-01-01
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
70
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guiyang, Baoding, Harbin
2025-12-26
Recruiting
Shenzhen Majory Biotechnology Co., Ltd.
Phase 1/2
45
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2025-12-24
Recruiting
Eye & ENT Hospital of Fudan University
Phase 2
116
Harbin, Jinan, Beijing, Shanghai, Tianjin
2025-12-22
Not yet open
Chunyan Ma
Observational
1,740
Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou, Nanjing, Nanchang, Changchun
2025-12-15
Recruiting
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
NCT07127822Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer
DrugIparomlimab and Tuvonralimab
Peking University
Phase 2
106
Shijiazhuang, Harbin, Zhengzhou, Nanjing, Xi'an, Qingdao, Taiyuan, Chengdu
2025-12-15
Recruiting
Shanghai Zhongshan Hospital
Phase 4
1,316
Hefei, Huizhou, Shenzhen, Harbin, Xinxiang, Wuhan, Changsha, Hengyang
2025-12-13
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-12-12
Active, closed
Beijing QL Biopharmaceutical Co.,Ltd
Phase 2
184
Handan, Langfang, Harbin, Luoyang, Chenzhou, Yueyang, Nanjing, Jinan
2025-12-12
Recruiting
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury
Vantive Health LLC
Not applicable
99
Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu
2025-12-11
Recruiting
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Changsha, Nanjing, Shanghai
2025-12-11
Recruiting
BeOne Medicines
Phase 1
105
Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang
2025-12-11
Recruiting
NWRD06 DNA Plasmid for HCC After Curative Resection.
NCT07324304Hepatocellular Carcinoma (HCC)
Newish Technology (Beijing) Co., Ltd.
Phase 2
30
Beijing, Harbin, Hangzhou
2025-12-08
Active, closed
Capital Medical University
Phase 3
692
Suzhou, Zhangzhou, Qinzhou, Langfang, Qinhuangdao, Tangshan, Harbin, Anyang
2025-12-05
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang
2025-12-04
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
180
Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang
2025-12-02
Recruiting
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3
60
Beijing, Harbin
2025-12-01
Recruiting
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Not yet open
First Hospital of China Medical University
Observational
2,640
Chongqing, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xiangyang, Changchun
2025-12
Active, closed
Dr. Willmar Schwabe GmbH & Co. KG
Phase 4
400
Anyang, Baotou, Beijing, Benxi, Chenzhou, Chifeng, Dalian, Harbin
2025-11-28
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO Resistant Squamous and Nonsquamous NSCLC
Takeda
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 2
189
Harbin
2025-11-25
Recruiting
Third Military Medical University
Phase 3
346
Bishan, Hechuan, Shapingba, Yuzhong, Lanzhou, Shijiazhuang, Harbin, Wuhan
2025-11-13
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
464
Fuzhou, Harbin, Nanjing, Jinan, Tianjin, Hangzhou
2025-11-12
Recruiting
Real-world Study of Aflibercept 8 mg in nAMD
NCT07640997Neovascular Age-Related Macular Degeneration (nAMD)
DrugAflibercept
Peking University People's Hospital
Observational
300
Beijing, Fuzhou, Shenzhen, Zunyi, Harbin, Nanyang, Wuhan, Hohhot
2025-11-11
Recruiting
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Harbin, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
NCT06902740Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
300
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2025-11-07
Recruiting
Takeda
Observational
200
Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin
2025-11-01
Not yet open
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
228
Beijing, Chongqing, Lanzhou, Guangzhou, Guiyang, Haikou, Harbin, Zhengzhou
2025-11
Recruiting
Eli Lilly and Company
Phase 3
1,205
Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin
2025-10-31
Recruiting
BioNTech SE
Phase 3
558
Changde, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing
2025-10-30
Active, closed
Kylonova (Xiamen) Biopharma co., LTD.
Phase 2
204
Beijing, Baotou, Changde, Chongqing, Dali, Daqing, Guangzhou, Harbin
2025-10-29
Recruiting
Fudan University
Not applicable
1,608
Guiyang, Shijiazhuang, Harbin, Wuhan, Changde, Changsha, Dalian, Jinan
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Luoyang, Zhengzhou
2025-10-23
Recruiting
Akeso
Phase 1
200
Harbin
2025-10-22
Recruiting
KD Treatment for Super-refractory Status Epilepticus
NCT07496749Super-refractory Status Epilepticus
Xuanwu Hospital, Beijing
Not applicable
84
Hefei, Beijing, Fuzhou, Nanning, Guiyang, Haikou, Shijiazhuang, Harbin
2025-10-20
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 2
140
Hefei, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Xiangyang, Changsha
2025-10-20
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Recruiting
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Not yet open
Eye & ENT Hospital of Fudan University
Phase 4
360
Chongqing, Fuzhou, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2025-10-08
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Hefei, Beijing, Changchun, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Harbin
2025-10-02
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
45
Fuzhou, Shijiazhuang, Harbin, Jinan, Tianjin
2025-10
Recruiting
Pfizer
Phase 3
680
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Wuhan
2025-09-29
Recruiting
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Recruiting
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou
2025-09-25
Recruiting
Capital Medical University
Not applicable
240
Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-24
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
490
Harbin, Shanghai
2025-09-24
Recruiting
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
NCT07141706Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1
253
Guangzhou, Harbin, Zhengzhou, Jinan
2025-09-23
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
86
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2025-09-22
Recruiting
Sanofi
Phase 4
218
Chengdu, Guangzhou, Hangzhou, Harbin, Ningbo, Xiamen
2025-09-22
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Harbin, Shanghai, Hangzhou
2025-09-22
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin
2025-09-22
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Recruiting
Sanofi
Phase 3
942
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin
2025-09-16
Active, closed
Eli Lilly and Company
Phase 3
800
Baotou, Beijing, Chongqing, Harbin, Hefei, Jinan, Luoyang, Nanjing
2025-09-15
Not yet open
Prime Gene Therapeutics Co., Ltd.
Phase 3
600
Beijing, Lanzhou, Baoding, Cangzhou, Langfang, Shijiazhuang, Daqing, Harbin
2025-09-15
Not yet open
Multicenter Validation Study on Autism Screening Using a Machine-assisted System
NCT07006948Autism Spectrum Disorder, Early Developmental Impairment, Language Development Disorders
Children's Hospital of Fudan University
Observational
1,000
Hefei, Xiamen, Liuzhou, Harbin, Kunshan, Xi'an, Shanghai, Chengdu
2025-09-15
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Hefei, Beijing, Fuzhou, Fyzhou, Xiamen, Lanzhou, Nanning, Harbin
2025-09-11
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
351
Harbin, Zhengzhou
2025-09-05
Active, closed
Capital Medical University
Not applicable
438
Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-04
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Recruiting
Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens
NCT07694648Respiratory Tract Infections (RTI), Respiratory Syndrome, Acute, Severe, Acute Respiratory Infections (ARIs)
Huashan Hospital
Observational
2,398
Beijing, Guangzhou, Zhuhai, Shijiazhuang, Harbin, Jiamusi, Shangqiu, Zhengzhou
2025-09-01
Not yet open
Sinomed Neurovita Technology Inc.
Not applicable
56
Harbin
2025-09-01
Not yet open
A Study on Cardiopulmonary Exercise Tolerance Standards for Healthy Chinese Population
NCT07108296Oxygen Consumption, Cardiorespiratory Fitness
Affiliated Hospital of Changchun University of Chinese Medicine
Observational
4,620
Beijing, Quanzhou, Guangzhou, Nanning, Daqing, Harbin, Puyang, Zhengzhou
2025-09-01
Recruiting
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
NCT07304232Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)
DrugChidamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
134
Shijiazhuang, Harbin, Tianjin
2025-09-01
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Beijing, Harbin, Zhengzhou
2025-08-28
Recruiting
Biotheus Inc.
Phase 2
100
Beijing, Guangzhou, Harbin, Wuhan, Changchun, Jinan, Shanghai, Chengdu
2025-08-19
Active, closed
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
By invitation
Huabo Biopharm Co., Ltd.
Phase 2
60
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin
2025-08-14
Recruiting
Akeso
Phase 3
760
Beijing, Fuzhou, Shijiazhuang, Harbin, Shanghai, Tianjin
2025-08-14
Recruiting
RemeGen Co., Ltd.
Phase 1/2
312
Beijing, Fuzhou, Xiamen, Guilin, Nanning, Harbin, Luoyan, Luoyang
2025-08-11
Active, closed
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
NCT07162181Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 2
13
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
Sanofi
Phase 3
723
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot
2025-08-06
Recruiting
Beijing Anzhen Hospital
Not applicable
4,100
Hefei, Beijing, Guangzhou, Shijiazhuang, Harbin, Luohe, Zhengzhou, Wuhan
2025-08-05
Recruiting
Pfizer
Phase 3
400
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Wuhan
2025-08-05
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
97
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2025-07-30
Recruiting
Dizal Pharmaceuticals
Phase 1/2
220
Beijing, Guangzhou, Harbin, Changsha, Nanjing, Shengyang, Jinan, Shanghai
2025-07-30
Recruiting
Celgene
Phase 3
400
Beijing, Fuzhou Fujian, Guangzhou, Harbin, Wuhan, Changsha, Hohhot, Suzhou
2025-07-28
Active, closed
Amgen
Phase 3
12,800
Bengbu, Beijing, Guangzhou, Huizhou, Yulin, Qinhuangdao, Shijiazhuang, Harbin
2025-07-25
Recruiting
Chinese Migrant Population Health Cohort
NCT07124949Cardiovascular Diseases, Metabolic Disorders, Ageing and Geriatric Health, Climate Adaptation
Jinwei Tian
Observational
26,000
Harbin
2025-07-23
Recruiting
Pfizer
Phase 3
714
Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang
2025-07-23
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
Beijing, Chongqing, Guangdong, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2025-07-18
Active, closed
Lixiaoling
Observational
30
Harbin
2025-07-10
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Not yet open
Harbin Medical University
Observational
10,000
Harbin
2025-07-01
Recruiting
Rectal NSAIDs With/Without PD Stent for PEP Prevention
NCT07117318Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement
DrugNSAIDs
Air Force Military Medical University, China
Not applicable
1,278
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Xi'an
2025-07-01
Recruiting
Safety and Efficacy of Ventricular Irrigation for Ventriculitis
NCT06358209Central Nervous System Infections
RenJi Hospital
Not applicable
310
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Shenzhen, Zhongshan, Harbin
2025-07-01
Recruiting
Heronova Pharmaceuticals
Phase 1
32
Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha, Jinan, Hangzhou
2025-06-30
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Hefei, Beijing, Guangzhou, Haikou, Qinhuangdao, Shijiazhuang, Daqing, Harbin
2025-06-25
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
642
Hefei, Beijing, Lanzhou, Shantou, Harbin, Kaifeng, Puyang, Zhengzhou
2025-06-23
Recruiting
First Affiliated Hospital of Ningbo University
Not applicable
380
Hefei, Harbin, Ningbo, Ninghai, Taizhou
2025-06-17
Recruiting
BeOne Medicines
Phase 3
630
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-06-11
Recruiting
Akeso
Phase 3
999
Harbin, Shanghai, Hangzhou
2025-06-11
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 2
250
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Guilin, Nanning, Harbin
2025-06-11
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
480
Beijing, Chongqing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2025-06-04
Recruiting
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin
DrugsIndomethacin·Diclofenac
Air Force Military Medical University, China
Not applicable
4,050
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City
2025-06-01
Not yet open
Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
NCT07010588Hepatocellular Carcinoma (HCC), Magnetic Resonance Imaging (MRI), Randomized Controlled Trial
Peking University People's Hospital
Not applicable
1,389
Beijing, Chongqing, Handan, Harbin, Wuhan, Changchun, Jinan, Qingdao
2025-06
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Not yet open
First Affiliated Hospital of Harbin Medical University
Observational
300
Harbin
2025-05-25
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Hefei, Fuzhou, Guangzhou, Harbin, Zhenngzhou, Wuhan, Xining, Shanghai
2025-05-22
Active, closed
Eli Lilly and Company
Phase 3
600
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-19
Active, closed
Eli Lilly and Company
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Active, closed
Eli Lilly and Company
Phase 3
1,400
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
Baotou, Beijing, Changchun, Guangzhou, Harbin, Kaili, Linfen, Nanyang
2025-05-15
Active, closed
Harbin Medical University
Not applicable
280
Harbin
2025-05-14
Active, closed
The Third Affiliated Hospital of Harbin Medical University
Observational
6,000
Harbin
2025-05-13
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
Beijing, Xiamen, Guangzhou, Harbin, Changsha, Changchun, Shanghai
2025-05-12
Recruiting
Arrowhead Pharmaceuticals
Phase 3
288
Beijing, Guangzhou, Guiyang, Harbin, Luoyang, Nanyang, Zhuzhou, Baotou
2025-04-24
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
120
Harbin, Hangzhou
2025-04-24
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
72
Beijing, Chongqing, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang
2025-04-11
Recruiting
Hoffmann-La Roche
Phase 3
450
Xiangyang, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jiangmen
2025-04-09
Recruiting
Beijing Anzhen Hospital
Not applicable
146
Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2025-04-08
Recruiting
Gilead Sciences
Phase 3
695
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-04-04
Not yet open
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
27
Harbin
2025-04
Not yet open
Betta Pharmaceuticals Co., Ltd.
Phase 2
100
Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou
2025-03-31
Active, closed
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 2/3
1,003
Beijing, Changzhou, Chengdu, Guangzhou, Guangzhusi, Guizhou, Hangzhou, Harbin
2025-03-31
Recruiting
AstraZeneca
Phase 1/2
304
Chengdu, Guangzhou, Harbin, Shanghai
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
510
Anyang, Beijing, Changchun, Changzhou, Chengdu, Fuzhou, Hangzhou, Harbin
2025-03-27
Recruiting
Jianmin Pharmaceutical Group Co., LTD.
Phase 2
216
Harbin, Changsha, Changchun, Jinan, Luzhou, Tianjin, Wenzhou
2025-03-26
Active, closed
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 3
40
Hefei, Lanzhou, Guangzhou, Shenzhen, Nanning, Tangshan, Harbin, Zhengzhou
2025-03-26
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
60
Dalian, Harbin, Shenyang, Tianjin
2025-03-25
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 3
194
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Nantong, Shanghai, Ürümqi
2025-03-24
Active, closed
Harbin Medical University
Not applicable
190
Harbin, Mudanjiang, Qiqihar
2025-03-23
Active, closed
RemeGen Co., Ltd.
Phase 1
121
Beijing, Foshan, Guangzhou, Jiangmen, Gulin, Nanning, Harbin, Hanyang
2025-03-13
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
55
Wuhu, Xiamen, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2025-03-12
Recruiting
BeOne Medicines
Phase 3
300
Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Xuzhou
2025-03-05
Not yet open
Ying Gao
Observational
4,460
Lanzhou, Harbin, Zhengzhou, Nanjing, Xuzhou, Changchun, Jining, Xian
2025-03-01
Recruiting
Daiichi Sankyo
Phase 3
726
Beijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou
2025-02-27
Recruiting
Summit Therapeutics
Phase 3
780
Fuyang, Beijing, Fuzhou, Guangzhou, Nanning, Guiyang, Haikou, Harbin
2025-02-27
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
54
Harbin, Shanghai
2025-02-26
Active, closed
Amgen
Phase 2
252
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Taiyuan, Chengdu, Tianjin
2025-02-26
Recruiting
Bristol-Myers Squibb
Phase 3
530
Beijing, Chongqing, Fuzhou, Xiamen, Shantou, Harbin, Wuhan, Changsha
2025-02-25
Recruiting
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
203
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-02-24
Recruiting
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
NCT06839105Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
DrugsAWT020·Taxol·Pemetrexed·Capecitabine
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
214
Fuzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Nanchang, Changchun
2025-02-21
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Bengbu, Jiangmen, Xingtai, Harbin, Luohe, Changsha, Nanjing, Nantong
2025-02-20
Recruiting
Shanghai Zhongshan Hospital
Phase 2/3
398
Harbin, Shanghai
2025-02-20
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
135
Bengbu, Wuwei, Guangzhou, Huizhou, Harbin, Luoyang, Nanyang, Zhengzhou
2025-01-28
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
300
Harbin, Zhengzhou
2025-01-21
Recruiting
AbbVie
Phase 2
150
Beijing, Fuzhou, Nanning, Harbin, Zhengzhou, Wuhan, Nanchang, Xi'an
2025-01-20
Recruiting
Beidahuang Industry Group General Hospital
Not applicable
200
Harbin
2025-01-15
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1
250
Hefei, Beijing, Fuzhou, Nanning, Harbin, Anyang, Luoyang, Zhengzhou
2025-01-10
Recruiting
First Affiliated Hospital of Harbin Medical University
Not applicable
20
Harbin
2025-01-07
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 1
48
Harbin, Jinan, Shanghai, Xinxiang
2025-01-07
Active, closed
Pfizer
Phase 3
1,035
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Harbin, Wuhan
2025-01-06
Recruiting
A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies
NCT06718634Relapsed or Refractory Lymphoid Malignancies
DrugBL-M08D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Harbin
2025-01-02
Recruiting
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
NCT06783569Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer, Colorectal Cancer
JiaRay Group
Phase 1
94
Harbin, Shenyang
2024-12-31
Recruiting
Cytokinetics
Phase 3
1,800
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Nanning, Harbin, Luoyang
2024-12-19
Active, closed
AbbVie
Phase 2
185
Beijing, Langfang, Harbin, Wuhan, Hangzhou
2024-12-13
Recruiting
First Affiliated Hospital of Ningbo University
Not applicable
216
Harbin, Hefei, Jingzhou, Ningbo, Ninghai, Taizhou
2024-12-13
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Harbin
2024-12-12
Recruiting
Hutchmed
Phase 3
412
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha
2024-12-12
Recruiting
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Recruiting
Diagnosis, Prognosis, and Mechanisms in Panvascular Disease
NCT07151183Panvascular Diseases, Cardiovascular Diseases
Jinwei Tian
Observational
1,000
Harbin
2024-12-01
Recruiting
Peking University People's Hospital
Not applicable
100
Beijing, Harbin
2024-12-01
Recruiting
Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)
NCT03547232Acute Pancreatitis, Complication, Mortality Rate, Organ Failure, Multiple
DrugIndomethacin
Peking Union Medical College Hospital
Phase 4
1,504
Beijing, Guiyang, Baoding, Harbin, Dengzhou, Nanyang, Huaian, Nantong
2024-12-01
Not yet open
First Affiliated Hospital of Harbin Medical University
Observational
90
Harbin
2024-12
Active, closed
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
NCT06649721Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis
DrugsClofazimine·Delamanid·Bedaquiline·Levofloxacin
Huashan Hospital
Phase 3
120
Hefei, Beijing, Xiamen, Nanning, Liupanshui, Shijiazhuang, Harbin, Jiamusi
2024-11-27
Recruiting
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
NCT06668103Non-Small Cell Lung Cancer With EGFR Mutation
DrugsABSK043·Furmonertinib
Abbisko Therapeutics Co, Ltd
Phase 2
54
Hefei, Harbin, Wuhan, Changchun, Shanghai
2024-11-25
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
42
Bozhou, Chuzhou, Hefei, Ma’anshan, Wuhu, Harbin, Zhengzhou, Wuhan
2024-11-14
By invitation
Multicenter Prospective Cohort Study of Hypertriglyceridemia Acute Pancreatitis
NCT06976099Acute Pancreatitis (AP), Hypertriglyceridemia Acute Pancreatitis
Peking Union Medical College Hospital
Observational
1,000
Beijing, Guangzhou, Zunyi, Harbin, Changsha, Nanjing, Yangzhou, Dalian
2024-11-13
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
DrugsABSK061·ABSK043·Folfox
Abbisko Therapeutics Co, Ltd
Phase 2
202
Guiyang, Shijiazhuang, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2024-11-13
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
80
Beijing, Lanzhou, Guangzhou, Guigang, Nanning, Harbin, Anyang, Puyang
2024-11-06
Active, closed
Daiichi Sankyo
Phase 1/2
137
Changchun, Hangzhou, Harbin, Jiamusi, Shanghai, Tiyuan, Zhengzhou
2024-10-30
Recruiting
Peking University People's Hospital
Observational
50
Beijing, Harbin, Nanjing, Shenyang, Xi'an
2024-10-26
Recruiting
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Hefei, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Chengde, Harbin
2024-10-24
Recruiting
QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
NCT06456528Cancer Treatment-Induced Thrombocytopenia
Qilu Pharmaceutical Co., Ltd.
Phase 2/3
235
Harbin, Nanjing
2024-10-22
Active, closed
Akeso
Phase 3
682
Harbin, Shanghai
2024-10-20
Recruiting
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Recruiting
Fudan University
Phase 4
756
Harbin, Changzhou, Nanjing, Yangzhou, Shanghai, Hangzhou, Ningbo
2024-10-18
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Huizhou, Nanchang
2024-10-18
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
35
Nanchang, Hangzhou, Harbin, Hefei, Jinhua, Nantong, Shanghai, Shanxi
2024-10-09
Active, closed
Harbin Medical University
Phase 2
30
Harbin
2024-10-08
Recruiting
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
Not yet open
Harbin Medical University
Phase 2
68
Harbin
2024-10
Active, closed
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
Recruiting
Bactiseal Catheter Safety Registry Study
NCT06276543Hydrocephalus
Integra LifeSciences Corporation
Observational
200
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu
2024-09-29
Active, closed
AstraZeneca
Observational
1,199
Beijing, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Hebei, Henan
2024-09-26
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
100
Harbin, Shanghai
2024-09-25
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
Beijing, Harbin, Shanghai
2024-09-12
Recruiting
DualityBio Inc.
Phase 1/2
360
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Nanning, Harbin, Luoyang
2024-09-03
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
27
Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang
2024-08-29
Recruiting
Bayer
Phase 3
444
Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Wuhan, Changsha
2024-08-28
Active, closed
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Harbin, Shanghai
2024-08-24
Active, closed
AstraZeneca
Phase 4
731
Beijing, Changchun, Dongguan, Foshan, Fuyang, Fuzhou, Ganzhou, Harbin
2024-08-23
Recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
400
Harbin, Shanghai
2024-08-15
Recruiting
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 2/3
574
Harbin, Shenyang
2024-08-15
Active, closed
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
270
Fuzhou, Foshan, Guangzhou, Jiangmen, Shenzhen, Nanning, Zunyi, Harbin
2024-08-06
Active, closed
Amgen
Phase 4
102
Beijing, Chongqing, Guangzhou, Harbin, Huaian, Nanjing, Suzhou, Xuzhou
2024-08-06
Recruiting
Phase 2 Study of WGI-0301 for Advanced HCC
NCT06309485Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.
Phase 2
60
Shanghai, Changsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
2024-07-31
Active, closed
magAssist, Inc.
Not applicable
236
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Lanzhou, Shanghai, Taiyuan
2024-07-31
Not yet open
Electroacupuncture Treatment of Behavioral and Psycological Symptoms in Patients With Alzheimer's Disease
NCT06523309BPSD (Behavioral and Psycological Symptoms of Dementia), Alzheimer's Dementia
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Observational
1,000
Beijing, Fuzhou, Harbin
2024-07-30
Recruiting
PulseSelect™ PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Beijing, Fuzhou, Harbin, Kunming, Nanjing, Shanghai, Shenzhen, Ürümqi
2024-07-23
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
DrugsTislelizumab·Bevacizumab
BeOne Medicines
Phase 1/2
630
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-07-23
Not yet open
Electroacupuncture for the Treatment of Agitated Symptoms of Alzheimer's Disease
NCT06495957Agitation Associated With Alzheimer's Dementia, Alzheimer's Dementia
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
224
Beijing, Fuzhou, Harbin
2024-07-20
Recruiting
Jazz Pharmaceuticals
Phase 3
286
Hefei, Beijing, Lanzhou, Harbin, Changsha, Changchun, Jinan, Chengdu
2024-07-19
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
60
Beijing, Changsha, Changzhi, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-07-17
By invitation
Harbin Medical University
Observational
562
Harbin
2024-07-15
Recruiting
Beijing Tiantan Hospital
Phase 3
4,674
Harbin, Dezhou, Liaocheng, Yantai
2024-07-11
Active, closed
Efficacy and Safety of Colchicine After PCI
NCT06472908Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine
DrugColchicine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
8,862
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Harbin, Zhengzhou, Enshi
2024-07-09
Active, closed
Novartis Pharmaceuticals
Phase 4
318
Hefei, Fuzhou, Guangzhou, Shenzhen, Zunyi, Harbin, Zhengzhou, Wuhan
2024-07-09
Active, closed
Tianjin Medical University General Hospital
Phase 2/3
102
Hefei, Lanzhou, Shijiazhuang, Harbin, Zhenzhou, Ordos, Changzhou, Suzhou
2024-07-09
Recruiting
Harbin Medical University
Observational
350
Harbin, Changchun
2024-07-07
Recruiting
China Medical University, China
Phase 4
1,176
Shenyang, Beijing, Chendu, Chifeng, Dalian, Harbin, Jinan, Kunming
2024-07-02
Recruiting
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
90
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jinan, Kunming
2024-06-30
Recruiting
Boehringer Ingelheim
Phase 1/2
910
Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
2024-06-28
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
140
Guangzhou, Zhuhai, Chengde, Harbin, Changsha, Changzhou, Binzhou, Shanghai
2024-06-27
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Cangzhou, Shijiazhuang, Harbin
2024-06-25
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1
63
Beijing, Harbin, Zhengzhou, Jinan, Shanghai
2024-06-24
Active, closed
Celgene
Phase 3
850
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou
2024-06-19
Active, closed
Hoffmann-La Roche
Phase 3
68
Beijing, Chengdu, Guangzhou, Harbin, Qingdao, Shanghai, Shenyang, Taiyuan
2024-06-17
Recruiting
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
NCT06574568Relapsed or Refractory Multiple Myeloma
DrugYKST02
Excyte Biopharma Ltd
Phase 1
70
Beijing, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Dalian, Jinan
2024-06-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2024-06-11
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Shanghai, Ürümqi, Xi'an
2024-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin, Anyang, Zhengzhou
2024-06-04
Active, closed
Amgen
Phase 1
120
Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun
2024-05-29
Recruiting
Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival
NCT06256354Cancer Surgery, Intraoperative Hypothermia, Targeted Temperature Management, Postoperative Delirium
Peking University First Hospital
Not applicable
3,992
Chizhou, Hefei, Ma’anshan, Beijing, Chongqing, Shenzhen, Shijiazhuang, Harbin
2024-05-29
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi
2024-05-24
Recruiting
A Study of GQ1010 in Subjects With Advanced Solid Tumors
NCT06464055Advanced Malignant Solid Tumors
DrugPhase II
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 1/2
260
Beijing, Harbin, Tianjin, Wuhan, Zhengzhou
2024-05-23
Active, closed
Bristol-Myers Squibb
Phase 4
84
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanchang
2024-05-15
Recruiting
AstraZeneca
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2024-04-29
Recruiting
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1
250
Guangzhou, Harbin, Nanchang, Shanghai, Kunming
2024-04-25
Active, closed
AstraZeneca
Phase 2
76
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanning
2024-04-21
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
138
Bengbu, Beijing, Chengde, Harbin, Zhengzhou, Wuhan, Zhuzhou, Shenyang
2024-04-17
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
187
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2024-04-17
Recruiting
Harbin Medical University
Not applicable
1,860
Beijin, Zunyi, Daqing, Harbin, Jiamusi, Mudanjiang, Zhengzhou, Wuhan
2024-04-16
Recruiting
BeOne Medicines
Phase 1
308
Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan
2024-04-12
Recruiting
Harbin Medical University
Phase 2
50
Harbin
2024-04-10
Not yet open
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2
80
Harbin
2024-04
Recruiting
Second Affiliated Hospital of Nanchang University
Phase 4
424
Hefei, Heihe, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-03-28
Active, closed
Wuhan YZY Biopharma Co., Ltd.
Phase 3
312
Beijing, Harbin
2024-03-25
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
DrugsBGB-43395·Fulvestrant
BeiGene
Phase 1
103
Beijing, Guangzhou, Harbin, Changsha, Shenyang, Xi'an
2024-03-11
Active, closed
AstraZeneca
Phase 3
594
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-03-04
Active, closed
Novartis Pharmaceuticals
Phase 3
1,466
Beijing, Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Changchun, Jinan
2024-02-28
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Hunan, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-02-22
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
164
Hefei, Fuzhou, Xi'an, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-02-22
Recruiting
RemeGen Co., Ltd.
Phase 2/3
90
Beijing, Xiamen, Harbin, Zhengzhou, Wuhan, Changsha, Xuzhou, Jinan
2024-02-22
Active, closed
Janssen Research & Development, LLC
Phase 2
305
Changzhou, Chengdoucun, Chengdu, Guangzhou, Hangzhou, Harbin, Huizhou, Nanjing
2024-02-16
Active, closed
Boehringer Ingelheim
Phase 3
428
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Taizhou
2024-02-09
Recruiting
Hansoh BioMedical R&D Company
Phase 2
220
Hefei, Fujian, Fuzhou, Guangzhou, Harbin, Anyang, Luoyang, Nanyang
2024-02-06
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
104
Chongqing, Fuzhou, Guiyang, Harbin, Changsha, Shenyang, Shanghai
2024-02-05
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
150
Chongqing, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Dalian, Shenyang
2024-02-01
Not yet open
Harbin Medical University
Phase 2
36
Harbin
2024-01-31
Recruiting
Huabo Biopharm Co., Ltd.
Phase 1/2
282
Baoding, Harbin, Luoyang, Zhengzhou, Lianyungang, Shenyang, Jinan, Linyi
2024-01-31
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
Hefei, Beijing, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-01-23
Recruiting
Daiichi Sankyo
Phase 3
75
Changchun, Harbin, Hefei
2024-01-05
Recruiting
First Affiliated Hospital of Harbin Medical University
Not applicable
200
Harbin
2024-01-01
Recruiting
Teligene US
Phase 2
66
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jinan
2023-12-27
Active, closed
Sanofi
Phase 3
943
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Jiazhuang
2023-12-27
Active, closed
Bristol-Myers Squibb
Phase 3
190
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-12-21
Recruiting
Harbin Medical University
Not applicable
90
Harbin
2023-12-20
Recruiting
Hansoh BioMedical R&D Company
Phase 2
170
Hefei, Beijing, Fuzhou, Guangzhou, Zhuhai, Nanning, Harbin, Zhengzhou
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Shijiazhuang, Harbin
2023-12-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
92
Guangzhou, Nanning, Cangzhou, Chengde, Tangshan, Xingtai, Harbin, Zhengzhou
2023-12-12
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2023-12-11
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
178
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang
2023-12-08
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
Recruiting
RemeGen Co., Ltd.
Phase 2
90
Beijing, Fuzhou, Kunming, Xiamen, Wuwei, Guangzhou, Harbin, Zhengzhou
2023-11-27
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 2
50
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2023-11-17
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Harbin, Changsha, Nanchang, Shenyang, Jinan, Anyang, Beijing, Changchun
2023-11-15
Active, closed
AstraZeneca
Phase 3
1,902
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin
2023-11-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-11-12
Active, closed
AstraZeneca
Phase 3
863
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou
2023-11-09
Recruiting
Allist Pharmaceuticals, Inc.
Phase 2
88
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-10-27
Recruiting
Study on c-Met Targeted PET/CT Imaging in NSCLC
NCT06911697PET/CT Imaging, NSCLC
Xilin Sun
Not applicable
88
Harbin
2023-10-26
Active, closed
Bristol-Myers Squibb
Phase 3
402
Hefei, Beijing, Chongqing, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-10-24
Recruiting
An Imaging Study of Polyvascular Disease
NCT06016608Polyvascular Disease
Harbin Medical University
Observational
1,100
Harbin
2023-10-18
Active, closed
Akeso
Phase 1/2
216
Harbin
2023-10-16
Recruiting
BeOne Medicines
Phase 1
337
Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu
2023-09-21
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
52
Hefei, Guangzhou, Liuzhou, Anyang, Luoyang, Shijiazhuang, Harbin, Xiangyang
2023-09-19
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1
128
Harbin, Shanghai, Hangzhou
2023-09-19
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3
254
Guangzhou, Liuzhou, Anyang, Luoyang, Shijiazhuang, Harbin, Wuhan, Nanjing
2023-09-08
Recruiting
Hoffmann-La Roche
Phase 3
230
Baoding, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan
2023-09-08
Active, closed
Amgen
Phase 4
36
Beijing, Fuzhou, Guangzhou, Harbin, Xi'an, Hangzhou
2023-08-17
Recruiting
DualityBio Inc.
Phase 1/2
862
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin
2023-08-17
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
364
Hefei, Beijing, Chongqing, Nanning, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-08-11
Active, closed
The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid Cancer
NCT06422702Pathologically Confirmed Differentiated Thyroid Carcinoma, All Patients Are in the Initial Treatment Phase, Normal Cognitive and Communicative Abilities, Capable of Reading and Understanding Questionnaires in Chinese, Ability to Use a Smartphone
Harbin Medical University
Not applicable
84
Harbin
2023-08-01
Recruiting
GlaxoSmithKline
Phase 3
892
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2023-08-01
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
67
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu, Hangzhou
2023-07-10
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
Guangzhou, Harbin, Nanjing, Changchun, Jinan, Shanghai, Chengdu, Hangzhou
2023-07-05
Active, closed
Peking University Hospital of Stomatology
Phase 2
110
Beijing, Baoding, Tangshan, Harbin, Chifeng, Hohhot, Changchun, Shenyang
2023-06-27
Recruiting
Hoffmann-La Roche
Phase 1/2
320
Changsha, Harbin, Shanghai
2023-06-20
Recruiting
Hoffmann-La Roche
Phase 3
420
Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang
2023-06-07
Active, closed
Eli Lilly and Company
Phase 3
3,127
Hefei, Beijing, Chongqing, Shenzhen, Haikou, Harbin, Luoyang Shi, Zhengzhou
2023-06-05
Active, closed
Biotheus Inc.
Phase 2
50
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan
2023-06-01
Active, closed
Amgen
Phase 3
509
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Shijiazhuang, Harbin
2023-05-31
Active, closed
Biotheus Inc.
Phase 2
31
Chongqing, Fuzhou, Harbin, Zhengzhou, Jingzhou, Wuhan, Changsha, Yongzhou
2023-05-17
Active, closed
Akeso
Phase 1/2
170
Harbin
2023-05-08
Active, closed
Shanghai Chest Hospital
Observational
305
Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai
2023-05-08
Recruiting
Statins for Treatment of Primary Intracerebral Hemorrhage
NCT07088250Cerebrovascular Disorders, Intracranial Hemorrhages, Intracranial Hemorrhage, Intracerebral Haemorrhage
The Second Hospital of Anhui Medical University
Not applicable
264
Anqing, Fuyang, Hefei, Huainan, Lu'an, Suzhou, Harbin, Kaifeng
2023-05-06
Recruiting
Sun Yat-sen University
Phase 3
540
Guangzhou, Guiyang, Harbin, Zhengzhou, Wuhan, Nanchang, Dalian, Shanghai
2023-04-30
Active, closed
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Recruiting
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou
2023-04-24
Active, closed
Klus Pharma Inc.
Phase 2
356
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-04-19
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
154
Chongqing, Harbin
2023-04-13
Recruiting
Shanghai Hongdian Medical CO., LTD
Not applicable
180
Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Harbin, Zhengzhou, Zhenzhou
2023-03-31
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Active, closed
SeQuent ® Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis
NCT06047964Stroke, Intracranial Atherosclerotic Stenosis
B. Braun Medical International Trading Company Ltd.
Not applicable
281
Beijing, Harbin, Nanyang, Changchun, Jining, Qingdao, Shanghai, Taiyuan
2023-03-23
Recruiting
Teligene US
Phase 2
60
Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2023-03-16
Active, closed
AbbVie
Phase 3
520
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-03-15
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Guangzhou, Nanning, Cangzhou, Shijiazhuang, Tangshan, Xingtai, Daqing, Harbin
2023-03-09
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
219
Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an
2023-03-09
Recruiting
OH2 Injection in Melanoma
NCT05868707Melanoma
DrugOH2
Binhui Biopharmaceutical Co., Ltd.
Phase 3
340
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin
2023-03-08
Active, closed
Pfizer
Phase 3
624
Hefei, Beijing, Fuzhou Fujian, Foshan, Guangzhou, Nanning, Harbin, Luoyang
2023-03-03
Recruiting
First Affiliated Hospital of Harbin Medical University
Observational
400
Harbin
2023-03-01
Recruiting
Sun Yat-sen University
Phase 3
176
Hefei, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Nanchang, Shanghai
2023-03-01
Active, closed
AstraZeneca
Phase 3
214
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan
2023-02-15
Active, closed
Genmab
Phase 3
900
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-02-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-02-06
Active, closed
The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection（BROAD）
NCT05659641Aortic Dissection, Aneurysm, Dissecting, Aneurysm, Vascular Diseases
Permed Biomedical Engineering Co., Ltd
Not applicable
259
Hefei, Chongqing, Fuzhou, Shijiazhuang, Harbin, Wuhan, Nanjing, Nanchang
2023-01-18
Recruiting
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Harbin, Changsha, Shanghai, Chengdu
2023-01-16
Recruiting
AstraZeneca
Phase 2
163
Beijing, Hangzhou, Harbin, Hefei, Kunming, Wuhan, Yinchuan, Zhengzhou
2023-01-16
Recruiting
Shandong Boan Biotechnology Co., Ltd
Phase 1
70
Harbin
2023-01-11
Recruiting
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 3
512
Harbin, Jinan, Shanghai
2022-12-20
Active, closed
Amgen
Phase 3
7,297
Beijing, Guangzhou, Huizhou, Nanning, Daqing, Harbin, Nanyang, Wuhan
2022-12-14
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-12-13
Recruiting
Huashan Hospital
Observational
1,255
Lanzhou, Harbin, Hohhot, Suzhou, Xuzhou, Shenyang, Jinan, Jining
2022-12-01
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
70
Hefei, Beijing, Fujian, Fuzhou, Foshan, Guangzhou, Shijiazhuang, Harbin
2022-11-15
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Baoding, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2022-11-11
Recruiting
MSD R&D (China) Co., Ltd.
Phase 1/2
203
Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xuzhou, Chengdu
2022-11-01
Recruiting
Eye & ENT Hospital of Fudan University
Not applicable
111
Harbin, Jinan, Shanghai
2022-11-01
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Fuzhou, Lanzhou, Guangzhou, Meizhou, Haikou, Chengde, Tangshan, Harbin
2022-10-24
Active, closed
Eli Lilly and Company
Phase 3
15,374
Beijing, Changchun, Changping, Chengdu, Chongqing, Haikou, Harbin, Hengshui Shi
2022-10-11
Recruiting
InventisBio Co., Ltd
Phase 3
640
Beijing, Harbin
2022-09-15
Recruiting
Teligene US
Phase 2
128
Bengbu, Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2022-09-01
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Recruiting
Allist Pharmaceuticals, Inc.
Phase 1/2
104
Beijing, Chongqing, Xiamen, Shenzhen, Nanning, Shijiazhuang, Harbin, Zhengzhou
2022-08-17
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Hefei, Beijing, Guangzhou, Hangzhou, Harbin, Wuhan, Changsha, Zhengzhou
2022-08-03
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
133
Chizhou, Fuzhou, Wuwei, Guangzhou, Meizhou, Shijiazhuang, Wuhan, Harbin
2022-07-26
Active, closed
Gilead Sciences
Phase 3
623
Beijing, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou, Harbin
2022-07-20
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Chongqing, Shijiazhuang, Harbin, Changsha, Nanjing, Suzhou, Changchun, Kunming
2022-07-07
Active, closed
Pfizer
Phase 2
35
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang
2022-07-07
Active, closed
Biotheus Inc.
Phase 1/2
42
Chongqing, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Yibin, Tianjin
2022-07-01
Active, closed
ArriVent BioPharma, Inc.
Phase 1
160
Hefei, Beijing, Chaoyang, Chongqing, Harbin, Zhengzhou, Wuhan, Xuzhou
2022-06-30
Active, closed
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
NCT05382364Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
DrugTucatinib
Pfizer
Phase 1
25
Harbin, Changsha, Changchun, Shanghai, Tianjin
2022-06-29
Active, closed
Biotheus Inc.
Phase 2
99
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nanchang
2022-05-27
Not yet open
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4
2,400
Harbin
2022-04-30
Active, closed
Eli Lilly and Company
Phase 3
925
Bengbu, Hefei, Wuhu, Beijing, Guangzhou, Harbin, Wuhan, Changsha
2022-04-14
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
DrugsJAB-3312·Glecirasib
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
100
Beijing, Tianjin, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Harbin
2022-04-02
Active, closed
AstraZeneca
Phase 3
1,035
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jiaxing
2022-03-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Hefei, Beijing, Fuzhou, Harbin, Zhengzhou, Wuhan, Changsha, Suzhou
2022-03-24
By invitation
Xiamen Amoytop Biotech Co., Ltd.
Not applicable
350
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Guanzhou, Harbin, Hefei
2022-03-18
Active, closed
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 3
397
Harbin
2022-03-14
Active, closed
AstraZeneca
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-02-21
Active, closed
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
NCT05194995Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
DrugsGlecirasib·Cetuximab
Allist Pharmaceuticals, Inc.
Phase 1/2
48
Beijing, Nanning, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2022-02-17
Recruiting
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
NCT05245058HER2-positive Advanced Solid Tumors
DrugSPH5030
Shanghai Pharmaceuticals Holding Co., Ltd
Early Phase 1
150
Hefei, Beijing, Guangzhou, Nanning, Shijiazhuang, Harbin, Anyang, Zhengzhou
2022-01-21
Recruiting
Second Xiangya Hospital of Central South University
Observational
20,000
Lanzhou, Shenzhen, Haikou, Harbin, Luoyang, Changsha, Nanjing, Changzhi
2022-01-01
Active, closed
Eli Lilly and Company
Phase 3
152
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Changchun, Xi'an, Jinan
2021-12-20
Active, closed
Hoffmann-La Roche
Phase 3
49
Guangzhou, Harbin, Wuhan, Jinan, Hangzhou, Beijing, Changchun, Changsha
2021-12-01
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Beijing, Foshan, Guangzhou, Nanning, Harbin, Jingzhou, Wuhan, Changsha
2021-11-23
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2021-11-17
Active, closed
AstraZeneca
Phase 3
148
Beijing, Changsha, Chongqing, Harbin, Jinan, Nanjing, Shanghai, Shenyang
2021-10-28
Active, closed
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Recruiting
Bayer
Phase 1/2
430
Beijing, Fuzhou, Harbin, Wuhan, Changsha, Nanjing, Taizhou, Jinan
2021-10-25
Active, closed
Gilead Sciences
Phase 2
53
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing
2021-10-12
Active, closed
Haihe Biopharma Co., Ltd.
Phase 2
93
Beijing, Chongqing, Guangdong, Haikou, Hainan, Hangzhou, Harbin, Hubei
2021-10-11
Active, closed
Hoffmann-La Roche
Phase 3
217
Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jining, Nanning, Shanghai
2021-09-30
Recruiting
First in Human, Dose Escalation Study of AN4005
NCT04999384Advanced Solid Tumor, Advanced Lymphoma
Adlai Nortye Biopharma Co., Ltd.
Phase 1
31
Beijing, Harbin, Wuhan
2021-09-27
Active, closed
First Affiliated Hospital of Harbin Medical University
Observational
200
Harbin
2021-09-01
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
102
Chongqing, Fuzhou, Ganzhou, Hangzhou, Harbin, Hefei, Mianyang, Nanjing
2021-08-31
Active, closed
Multi-centre Study to Evaluate ACAF Versus Laminoplasty in Treating Cervical Ossification of the Posterior Longitudinal Ligament
NCT04968028Ossification of Posterior Longitudinal Ligament, Cervical Spondylosis With Myelopathy
Shanghai Changzheng Hospital
Not applicable
167
Beijing, Shenzhen, Harbin, Jining, Qingdao, Shanghai, Taiyuan, Xi’an
2021-08-17
Recruiting
Shengjing Hospital
Phase 4
110
Harbin, Changchun, Dalian, Panjin, Shenyang
2021-07-19
Recruiting
Shengjing Hospital
Observational
1,000
Harbin, Changchun, Dalian, Panjin, Shenyang
2021-07-19
Recruiting
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
DrugGivastomig
I-Mab Biopharma US Limited
Phase 1
330
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Shanghai
2021-06-29
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
DrugHuaier
Fudan University
Phase 4
1,072
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2021-06-18
Active, closed
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
88
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming
2021-06-07
Active, closed
Daiichi Sankyo
Phase 3
490
Heifi, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Changshan
2021-05-21
Active, closed
Hoffmann-La Roche
Phase 3
1,188
Chengdu, Chongqing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Xi'an
2021-05-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Bengbu, Beijing, Chongging, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou
2021-04-14
Active, closed
Hoffmann-La Roche
Phase 3
270
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou
2021-02-23
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Liuzhou, Harbin, Xinxiang
2021-02-23
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2021-02-02
Active, closed
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Wuhan
2021-01-10
Active, closed
Daiichi Sankyo
Phase 3
1,600
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2020-12-04
Active, closed
AstraZeneca
Phase 1/2
702
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Harbin, Jining
2020-11-12
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsCT041 autologous CAR T-cell·Apatinib·Irinotecan
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Rows per page Showing 1–500 of 548
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/harbin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 548 of those studies with a site in Harbin.

How many clinical trials are recruiting in Harbin?

309 of the 548 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 57 have not yet opened recruitment, 176 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Harbin), 548 studies
PhaseStudiesRecruitingShare
Phase 31657030.1%
Phase 21105820.1%
Phase 1/2715813%
Phase 1584310.6%
Not applicable553410%
Observational50289.1%
Phase 42193.8%
Phase 2/31783.1%
Early Phase 1110.2%

Most active sponsors

Lead sponsors with the most studies (Harbin)
Lead sponsorStudiesRecruiting
Harbin Medical University247
AstraZeneca235
Eli Lilly and Company215
BeOne Medicines1513
Hoffmann-La Roche155
Bristol-Myers Squibb149
Merck Sharp & Dohme LLC145
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.119
Amgen101
Daiichi Sankyo95
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.